Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Dirk Schadendorf, Axel Hauschild et al.|New England Journal of Medicine|2020Cited by 406
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III MelanomaAxel Hauschild, Georgina V. Long, Reinhard Dummer et al.|Journal of Clinical Oncology|2018Cited by 255
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Dirk Schadendorf, Georgina V. Long et al.|Zurich Open Repository and Archive (University of Zurich)|2022Cited by 146
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paul B. Chapman, Paolo A. Ascierto et al.|European Journal of Cancer|2020Cited by 69
LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trialPaul Nathan, Dirk Schadendorf, Reinhard Dummer et al.|Annals of Oncology|2020Cited by 68